In controlled clinical trials, Ventavis® improved a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and the absence of clinical deterioration.
In December 2006, data from the Phase II/III clinical trial STEP, evaluating the safety and added benefit of using Ventavis® (iloprost) inhalation solution therapy in patients with PAH already undergoing treatment with bosentan, were published. The analysis of this study showed that the combination of Ventavis® added to bosentan therapy was well tolerated, and was consistent with the safety profile observed in patients receiving only iloprost.
